Please assess the completion status of the following clinical trial:

Trial Title: A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent for study participation obtained before undergoing any study-specific procedures~* Documented congenital FXIII deficiency which requires prophylactic treatment with a FXIII containing product.~* Males and females of any age with congenital FXIII deficiency~* Received full hepatitis B vaccination and/or is hepatitis B surface antibody positive~Exclusion Criteria:~* Diagnosis of acquired FXIII deficiency~* Administration of a FXIII-containing product, including blood transfusions or other blood products within 4 weeks prior to the planned Day 0~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Known or suspected to have antibodies towards FXIII~* Use of any other investigational medicinal product within 4 weeks prior to the Baseline Visit (Day 0)~* Known Positivity for human immunodeficiency virus (HIV) or a positive result for HIV at the Screening Visit of this study or the FXIII study 2002 (NCT00883090).~* Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) concentration \>2.5 times the upper limit of normal at the Screening Visit of this study or at the Day 56 Visit of Factor XIII Study BI71023_2002 (NCT00883090)~* Fibrinogen level less than 85% of the lower limit of normal at the Screening Visit of this study or the Factor XIII Study BI71023_2002 (NCT00883090)~* Active bleeding ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 and/or ≥ moderate between the Screening and Baseline Visits~* Pregnant or breast-feeding~* Intention to become pregnant during the course of the study~* Female subjects of childbearing potential not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study~* Suspected inability (e.g., language problems) or unwillingness to comply with study procedures or history of noncompliance

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FXIII (Type: EXPERIMENTAL): All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).

Based on this trial design, predict the completion outcome and termination type (if applicable).